


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

PROFIT WARNING

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of C-MER Eye Care Holdings Limited (the “**Company**” which together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the financial information currently available to the Company, while it is expected that the revenue of the Group is expected to increase by more than 20% for the year ended 31 December 2020 (“**FY2020**”) as compared with the year ended 31 December 2019 (“**FY2019**”), the Group is expected to record a net loss not exceeding HK\$9 million for FY2020 as compared with a net profit of approximately HK\$39.1 million in FY2019. This is primarily due to (i) the impact of COVID-19, which generally affected the Group’s operations in mainland China and Hong Kong in the first half of 2020, and the Group’s hospitals in mainland China were locked down for up to 6 weeks in the first quarter of 2020; and (ii) the net losses of the new eye hospitals of the Group in Shanghai and Kunming, which were acquired and commenced operations in FY2019, and were still in their developmental stages.

Since the Group is recovering reasonably well from the COVID-19 outbreaks in mainland China and Hong Kong, the financial performance of the Group is expected to gradually improve.

As the Company is still in the process of finalising the results for FY2020, the information contained in this announcement is based on the management’s preliminary review on the management accounts of the Group and current information available to the Board and has not been audited and confirmed by the Company’s auditors or the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the annual results announcement of the Company for FY2020 which is expected to be published by the end of March 2021.

Shareholders and prospective investors of the Company are advised to exercise caution when dealings in the shares of the Company.

By order of the Board

C-MER Eye Care Holdings Limited

Dr. LAM Shun Chiu Dennis JP

Chairman and Chief Executive Officer and Executive Director

Hong Kong, 12 March 2021

As of the date of this announcement, the Board comprises four executive Directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent and Mr. LI Chunshan and six independent non-executive Directors, namely, Dr. LI Kwok Tung Donald, Mr. MA Andrew Chiu Cheung, Mr. CHAN Chi Leong, Ms. BENTLEY Annie Liang, Dr. Rex AUYEUNG Pak-kuen and Mr. IP Shu Kwan Stephen.